| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A654 | Anti-ACVR2A Antibody (Ab-14E1) Featured |
|
|
| A655 | Bimagrumab Featured | Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness. |
|
| A656 | Acceleron patent anti-ActRIIB Featured |
|
|
| A657 | IMGC-936 Featured |
|
|
| A658 | Enibarcimab Featured | Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research. |
|
| A659 | Anti-AGER/RAGE Antibody (XT-M4) Featured |
|
|
| A660 | Praluzatamab Featured | Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers. |
|
| A661 | Anti-ALCAM/CD166 Antibody (AT002) Featured |
|
|
| A662 | Seagen Patent Anti-Alpp Featured |
|
|
| A663 | Prasinezumab Featured | Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research. |
|
| A664 | Cinpanemab Featured | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease. |
|
| A665 | Murlentamab Featured | Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
|
| A666 | Gantenerumab Featured | Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research. |
|
| A667 | Crenezumab Featured | Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research. |
|
| A668 | Donanemab Featured | Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. |
|
| A669 | Solanezumab Featured | Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease. |
|
| A670 | GSK-933776 Featured |
|
|
| A671 | Bapineuzumab Featured | Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD). |
|
| A672 | Amgen patent anti-beta amyloid Featured |
|
|
| A673 | Anti-Amyloid Beta Antibody (CNTO 2125) Featured |
|
|
| A674 | Anti-Amyloid Beta Antibody (DLX212) Featured |
|
|
| A675 | Georgetown U. patent anti-Amyloid Beta Featured |
|
|
| A676 | Kumamoto U. patent anti-Amyloid Beta Featured |
|
|
| A677 | Merck anti-Amyloid beta 19.3 Featured |
|
|
| A678 | Rockefeller U. patent anti-Amyloid Beta Featured |
|
|
| A679 | U.Illinois scFv59 Featured |
|
|
| A680 | U.Zurich patent anti-Amyloid Beta Featured |
|
|
| A681 | Zansecimab Featured | Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation. |
|
| A682 | Nesvacumab Featured | Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. |
|
| A683 | MEDI3617 Featured |
|
